EnPlusOne is hiring! We have an exciting role to fill in our chemistry department. Who are we looking for? 🧬 Skilled chemist or biolchemist who wants to be on the cutting edge of enzymatic RNA synthesis 🚀 Shares our passion and vision to deliver better RNA to the world 🥉 Are hungry, humble, and smart Please apply by sending your CV and cover letter to careers@enplusonebio.com
EnPlusOne Biosciences
Biotechnology Research
Watertown, Massachusetts 2,044 followers
Harnessing the power and flexibility of enzymes to deliver RNA to the world
About us
EnPlusOne is on a mission to bring RNA and RNA solutions to the world. Its ezRNA™ synthesis platform is a stepwise innovation that can incorporate a diverse array of nucleotide modifications and promises a manufacturing process that can sustainably deliver therapeutic RNA at commercial scales. In addition to direct RNA synthesis, EnPlusOne's ezRNA™ platform supports a vast array of RNA solution applications. For more information, please visit www.enplusonebio.com
- Website
-
www.enplusonebio.com
External link for EnPlusOne Biosciences
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Watertown, Massachusetts
- Type
- Privately Held
Locations
-
Primary
Get directions
313 Pleasant St
4W
Watertown, Massachusetts 02472, US
Employees at EnPlusOne Biosciences
Updates
-
We are thrilled to collaborate with The Wyss Institute on a significant award funded by ARPA-H. We look forward to accelerating our progress on novel RNA modifications and scale utilizing our ezRNA™ synthesis platform. Now the challenging and rewarding work begins! 𝗙𝘂𝗹𝗹 𝗥𝗲𝗹𝗲𝗮𝘀𝗲: https://lnkd.in/g4VaBViy
-
We are excited to share EnPlusOne's core platform technology has been peer-reviewed and published in Nature Biotechnology. Congratulations to our Chief Scientific Officer and co-first author Jonathan Rittichier and the entire team. We have continued to make significant progress from where our paper leaves off and look forward to advancing our platform to deliver better RNA at scale! 🧬 𝗥𝗲𝗮𝗱 𝗳𝘂𝗹𝗹 𝗽𝗮𝗽𝗲𝗿 𝗵𝗲𝗿𝗲: https://lnkd.in/eHRpKG5b
-
We are excited to announce publication of our core technology in Nature Biotechnology! Open Access Paper: https://lnkd.in/eHRpKG5b
RNA drugs are the next frontier of medicine, but manufacturing them requires an expensive and labor-intensive process that limits production and produces metric tons of toxic chemical waste. In a new paper published today in Nature Biotechnology, a team of researchers from the Wyss Institute and Harvard Medical School report a new, enzyme-based RNA synthesis method that can produce strands of RNA with both natural and modified nucleotides without the environmental hazards. This approach enables the rapid scale-up needed to meet the growing demand for RNA therapeutics, and is being commercialized by Wyss startup EnPlusOne Biosciences. Northpond Ventures Jonathan Rittichier Daniel Wiegand Erkin Kuru #Oligonucleotides #RNA #Therapeutics #StartupNews https://lnkd.in/eqc3rXqp
-
-
We're very excited to share EnPlusOne Bioscience's significant progress so far this year, especially the enzymatic synthesis of Leqvio® antisense strand. We're proud of what we've accomplished to this point as we continue our journey of harnessing the power of enzymes to deliver better RNA at scale. Read more details here! https://lnkd.in/gcsxs9rn
-
EnPlusOne is hiring! We have two exciting roles to fill in our chemistry and synthesis departments. What kind of people are we looking for? 🧬 Skilled chemists and biologists who want to be on the cutting edge of enzymatic RNA synthesis 🚀 Shares our passion and vision to deliver better RNA to the world 🥉 Are hungry, humble, and smart See below for the job descriptions and ways to apply!
-
We are excited to present at TIDES this week to share recent advancements of our ezRNA™ synthesis platform. Our enzymatic RNA synthesis platform is poised to unlock scale and novel modifications in RNA therapeutics manufacturing. Be sure to check out our CSO Jonathan Rittichier's talk at 9a on 5/16 where he will discuss this progress in detail.